Cargando…
Neoadjuvant endocrine therapy in primary breast cancer: indications and use as a research tool
Neoadjuvant endocrine therapy has been increasingly employed in clinical practice to improve surgical options for postmenopausal women with bulky hormone receptor-positive breast cancer. Recent studies indicate that tumour response in this setting may predict long-term outcome of patients on adjuvan...
Autores principales: | Chia, Y H, Ellis, M J, Ma, C X |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2966629/ https://www.ncbi.nlm.nih.gov/pubmed/20700118 http://dx.doi.org/10.1038/sj.bjc.6605845 |
Ejemplares similares
-
First-line endocrine treatment of breast cancer: aromatase inhibitor or antioestrogen?
por: Wong, Z-W, et al.
Publicado: (2004) -
Neoadjuvant therapy for resectable pancreatic cancer
por: Rahman, Sheikh Hasibur, et al.
Publicado: (2017) -
Endocrine therapy in prostate cancer: time for reappraisal of risks, benefits and cost-effectiveness?
por: Bourke, L, et al.
Publicado: (2013) -
Borderline resectable pancreatic cancer and vascular resections in the era of neoadjuvant therapy
por: Mikulic, Danko, et al.
Publicado: (2021) -
Neoadjuvant therapy for pancreatic ductal adenocarcinoma: Opportunities for personalized cancer care
por: Hamad, Ahmad, et al.
Publicado: (2021)